Natera Inc's stock rose by 4.05% today, reaching a 52-week high. This increase comes as the Nasdaq-100 is up 0.82% and the S&P 500 is up 0.61%.
The surge is attributed to Natera presenting significant data from the ALTAIR trial at ASCO GI 2026, showing a median disease-free survival of 9.23 months for FTD/TPI treatment compared to 5.55 months for placebo, indicating strong efficacy in colorectal cancer patients. This analysis highlights the potential of FTD/TPI in clinical applications and showcases Natera's leadership in ctDNA dynamic monitoring.
These findings not only enhance Natera's reputation in the oncology space but also suggest a promising future for personalized cancer treatment strategies, potentially attracting more investors and driving further stock appreciation.
Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 252.88 USD with a low forecast of 172.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 252.88 USD with a low forecast of 172.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 235.930
Low
172.00
Averages
252.88
High
300.00
Current: 235.930
Low
172.00
Averages
252.88
High
300.00
TD Cowen
Buy
maintain
$240 -> $280
2026-01-07
Reason
TD Cowen
Price Target
$240 -> $280
AI Analysis
2026-01-07
maintain
Buy
Reason
TD Cowen raised the firm's price target on Natera to $280 from $240 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.
Citi
NULL -> Buy
initiated
$300
2026-01-07
Reason
Citi
Price Target
$300
2026-01-07
initiated
NULL -> Buy
Reason
Citi initiated coverage of Natera with a Buy rating and $300 price target. The company is an "established player" in the women's and organ health markets, but its "dominant position" in the growing molecular residual disease market is the focus for investors, the analyst tells investors in a research note. Citi believes the shares warrant a premium multiple with a "significant" growth runway ahead for Natera.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NTRA
Unlock Now
Guggenheim
Buy
maintain
$230 -> $270
2026-01-05
Reason
Guggenheim
Price Target
$230 -> $270
2026-01-05
maintain
Buy
Reason
Guggenheim raised the firm's price target on Natera to $270 from $230 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Canaccord
Buy
maintain
$260 -> $285
2025-12-22
Reason
Canaccord
Price Target
$260 -> $285
2025-12-22
maintain
Buy
Reason
Canaccord raised the firm's price target on Natera to $285 from $260 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for Natera.
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
